Answers are grounded in this paper and cite their sources.
We conclude that alternative dosing strategies used by oncologists such as prescribing palbociclib for three weeks on, two weeks off may achieve comparable disease control while mitigating neutropenic toxicities when compared to standard monograph dosing recommendations, prolonging treatment tolerability and adherence. Further large-scale studies are needed to confirm these results for future clinical adoption.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: